European Respiratory Drug Market 2019 Growth, COVID Impact, Trends Analysis Report 2025
European respiratory drug market was $11.1 billion in 2018 and is anticipated to grow at a substantial rate of 7.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in Europe. Major countries that will contribute to the respiratory drug market within the region includes UK, Germany, France, Italy and Spain. A significant number of companies, research, patient base has been observed in the market due to which a significant growth can be observed in the market. According to the International Monetary Fund (IMF), Europe is home to around 740 million people and the GDP of the European Union was $19.7 trillion in 2017. As per Organization for Economic Co-operation and Development (OECD), the self-reported asthma rate and COPD rate by European Union countries were 6.1% and 4.0% respectively and it has been found out that the rate of prevalence of diseases are higher in women as compared to men. This is expected to drive the regional business growth of the respiratory drug market.
To Request a Sample of our Report on European
Respiratory Drug Market: https://www.omrglobal.com/request-sample/european-respiratory-drug-market
The European respiratory drug market is segmented on the
basis of route of administration, application, and end-user. Based on the route
of administration, the market is classified into oral, injectable, and
inhalable. Moreover, on the basis of application, the market has been
classified into asthma and COPD diseases. The asthma disease application
segment dominated the regional market in 2018 and is further estimated to
follow the same trend over the forecast period. This is mainly due to the high
prevalence of asthma in the economies of the region such as UK, Germany, France,
and others. In addition, based on the end-user, homecare and hospitals and
clinics have been analyzed.
(Get 15% Discount on Buying this Report)
A
full Report of European Respiratory Drug Market is Available @ https://www.omrglobal.com/industry-reports/european-respiratory-drug-market
European Respiratory Drug Market Segmentation
By Route of Administration
·
Oral
·
Injectable
·
Inhalable
By Application
·
Asthma
·
Chronic Obstructive Pulmonary Disease (COPD)
·
European Respiratory Drug Market by End-User
·
Homecare
·
Hospitals and Clinics
Regional Analysis
·
UK
·
Germany
·
France
·
Italy
·
Spain
Rest of Europe
Company Profiles
·
Air Liquide S.A.
·
Aradigm Corp.
·
AstraZeneca PLC
·
Baxter International Inc.
·
Boehringer Ingelheim International GmbH
·
F. Hoffmann-La Roche Ltd.
·
GlaxoSmithKline PLC
·
Merck & Co.
·
Novartis AG
·
Omron Healthcare Inc.
·
Pfizer Inc.
·
Pulmatrix Inc.
·
ResMed Corp.
·
Savara, Inc.
·
Sunovion Pharmaceuticals
·
Takeda Pharmaceutical Company Ltd.
·
Teva Pharmaceuticals Industries Ltd.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment